Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT03585465

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors (Metro-PD1)

Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory / Relapsing Solid Tumors

Sponsor: Anticancer Fund, Belgium

Conditions Childhood Solid Tumor

Interventions Capecitabine Cyclophosphamide Nivolumab Vinblastine

Updated 14 times since 2018 Last updated: Jan 22, 2026 Started: Mar 26, 2019 Primary completion: Dec 31, 2025 Completion: Jan 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Childhood Solid Tumor and is currently ongoing. Anticancer Fund, Belgium leads this study, which shows 14 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

14 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
May 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2024 — May 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 9 earlier versions

Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Suspended → Active Not Recruiting
Mar 2024 — Jun 2024 [monthly]

Suspended PHASE1_PHASE2

Status: Recruiting → Suspended
Aug 2023 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2
Jul 2022 — Aug 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2021 — Jul 2022 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Jun 2021 [monthly]

Recruiting PHASE1_PHASE2
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Apr 2019 — Sep 2020 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Aug 2018 — Apr 2019 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anticancer Fund, Belgium
Bristol-Myers Squibb
CTD-CNO
Centre Oscar Lambret
ECS-Progastrin SA

Data source: Centre Oscar Lambret

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Brussels, Belgium , Ghent, Belgium , Leuven, Belgium , Lille, France , Lyon, France , Marseille, France , Nancy, France , Nantes, France , Paris, France , Strasbourg, France and 1 more location